BusinessPhoto: HT WorldRoche Reports Higher Q3 Sales Driven by Pharma and Diagnostics Growth
Roche Holding reported third-quarter sales of 16.13 billion Swiss francs ($19.57 billion), up from 14.92 billion francs last year, driven by growth in its pharmaceuticals and diagnostics units. Sales rose 7% excluding currency effects, with key drugs like Ocrevus, Hemlibra, and Vabysmo boosting pharma sales by 8%. Diagnostics sales increased 5%, offsetting impacts from China's healthcare reforms. Roche maintained its full-year sales and earnings guidance.
HT World·



